

Effects of *Hylomecon vernalis* ethanol extracts on cell cycle and apoptosis of colon cancer cells

JING SUN¹, XIN ZHANG¹, YANG SUN², ZHI-SHU TANG¹ and DONG-YAN GUO¹

¹College of Pharmacy, Shannxi University of Chinese Medicine, Xianyang, Shannxi 712046; ²Department of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shannxi 710032, P.R. China

Received January 20, 2016; Accepted January 19, 2017

DOI: 10.3892/mmr.2017.6426

Abstract. *Hylomecon vernalis* Maxim. has traditionally been used to promote blood circulation, alleviate pain, dissipate stasis, and reduce swelling. The aim of the present study was to investigate the effect and potential mechanism of *H. vernalis* Maxim. ethanol extracts (HVMEE) on the growth and apoptosis of human colon cancer HT-29 and SW620 cells. *H. vernalis* samples were extracted three times with ethanol, dried, and concentrated into powder. The components of HVMEE were investigated using high performance liquid chromatography in tandem with mass spectrometry analysis. MTT assay was used to investigate the effect of HVMEE on viability of human colon cancer HT-29 and SW620 cells. Apoptosis of HT-29 and SW620 cells was evaluated using flow cytometric analysis. Expression levels of apoptosis and cell cycle-related proteins were assessed by western blot. The findings demonstrated that the alkaloid content of HVMEE was as high as 89.67%, and it effectively inhibited viability in HT-29 and SW620 cells, with IC₅₀ values of 0.105±0.022 mg/ml and 0.146±0.013 mg/ml, respectively. In addition, HVMEE induced apoptosis in HT-29 and SW620 cells, by increasing caspase-3, caspase-9 and BCL2 associated X expression, and reducing Bcl-2 expression. The present study suggests that HVMEE has a potential role in the treatment of colorectal cancer.

Introduction

Colorectal cancer (CRC) is one of the most common cancers worldwide, with an annual incidence rate of 1.2 million and an annual mortality rate of over 600,000 individuals (1,2). Despite considerable advances in surgical techniques and neoadjuvant chemotherapy, the survival rate of CRC remains poor (3). Antimetabolites, such as 5-fluorouracil (5-FU), have therapeutic properties for patients with CRC; however, the side

effects, which include myelotoxicity and GI toxicities (such as diarrhea and stomatitis), limit their long-term use. Thus, there is an urgent need for the development of new drugs with more specific effects and low toxicity.

Natural products have been shown to be excellent and reliable sources in pharmaceutical development of anti-cancer drugs (4,5). Sinomenine (SIN), an alkaloid from *Sinomenium acutum*, inhibits proliferation in SW1116 colorectal cancer cells by promoting G₁ phase arrest, with concomitant suppression of COX-2 expression (6). Bisleuconothine A, a bisindole alkaloid, inhibits cell proliferation and induces apoptosis in HCT116 and SW480 colorectal cancer cells, by increasing caspase cleavage (7). Furthermore, it dramatically suppresses Wnt target gene expression in an *in vivo* HCT116 xenograft model, through upregulation of β -catenin phosphorylation and subsequent Wnt signaling inhibition (7). Piperlongumine (PPLGM), an alkaloid isolated from the long pepper (*Piper longum* L.), selectively triggers cancer cell death in HCT116 colorectal cancer cells, through activation of the JNK signaling pathway (8).

Hylomecon vernalis Maxim. has long been used in traditional Chinese medicine for improving the local blood supply, dissipating blood stasis, and relieving pain. Alkaloids have multiple biological activities, including antitumor, anti-inflammatory, and analgesic effects. In the present study, the aim was to investigate the effect of HVMEE on viability and apoptosis of HT-29 and SW620 human colorectal cancer cells and its potential mechanism.

Materials and methods

Chemicals and reagents. MTT was purchased from Sigma-Aldrich; Merck Millipore (Darmstadt, Germany). Polyclonal rabbit anti-human cleaved caspase-3 (1:1,000; cat. no. 9661S), monoclonal rabbit anti-human cleaved caspase-8 (1:1,000; cat. no. 9496S), polyclonal rabbit anti-human cleaved caspase-9 (1:1,000; cat. no. 9505S), monoclonal mouse anti-human BCL-2 (1:1,000; cat. no. 15071S), polyclonal rabbit anti-human Bax (1:1,000; cat. no. 2772S), monoclonal rabbit anti-human cyclin D1 (1:1,000; cat. no. 2978S), monoclonal rabbit anti-human CDK4 (1:1,000; cat. no. 12790S), monoclonal rabbit anti-human CDK6 (1:1,000; cat. no. 13331S) and monoclonal rabbit anti-human p21 (1:1,000; cat. no. 2947S) primary antibodies were purchased

Correspondence to: Dr Jing Sun, College of Pharmacy, Shannxi University of Chinese Medicine, 55 Century Avenue, Xianyang, Shannxi 712046, P.R. China
E-mail: 124613320@qq.com

Key words: *Hylomecon vernalis*, apoptosis, cancer cell, cell cycle

from Cell Signaling Technology, Inc. (Danvers, MA, USA). N-Benzyloxycarbonyl-Val-Ala-Asp (O-Me) fluoromethyl ketone (Z-VAD-FMK) was purchased from Beyotime Institute of Biotechnology (Haimen, China). The monoclonal mouse anti-human β -actin primary antibody was obtained from Abcam (1:1,000; cat. no. ab8226; Cambridge, UK). Goat anti-mouse and goat anti-rabbit secondary antibodies were purchased from Thermo Fisher Scientific, Inc., (1:5,000; cat. nos. A16072 and A16110, respectively; Waltham, MA, USA).

Extraction of HVMEE. *H. vernalis* Maxim. was purchased from Shaanxi Panlong Pharmaceutical Co., Ltd. (Shangluo, China). Briefly, the dried root of *H. vernalis* Maxim. (10.0 kg) was extracted with 70% ethanol three times. The extracts were combined, concentrated, and dried at 80°C to obtain the HVMEE. High-performance liquid chromatography (HPLC) in tandem with mass spectrometry analysis was used to assess the main ingredients in the extracts. HPLC was conducted in tandem with mass spectrometry using an Agilent 1260 HPLC and AB SCIEX 4500Q trap triple quadrupole mass spectrometer with ESI source: Mobile phase 0.1% (v/v) (A) formic acid aqueous solution and (B) acetonitrile; injection volume 5 μ l; column temperature 35°C, using a gradient elution mode. Run times from 0-10 min up to 15% B and from 11-20 min up to 27% B. The HPLC system consisted of a C18 column (3.9x300 mm, 10 μ m) with 1 ml/min flow rate. The MassHunter (Agilent Technologies, Inc., Santa Clara, CA, USA) system was used.

Cell culture. Human CRC cell lines HT-29 and SW620 were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in RPMI-1640 (Thermo Fisher Scientific, Inc.) supplemented with 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc.; cat. no. 10437-028), 100 U/ml penicillin, and 100 U/ml streptomycin in an atmosphere of 95% oxygen and 5% CO₂ at 37°C.

Cell viability assay. HT-29 and SW620 cells were seeded in 96-well plates at a density of 2x10⁴ cells/well for 24 h, then cells were treated with 0.01, 0.03, 0.1, 0.3, 1, and 3 mg/ml HVMEE for 24 h in complete medium. Following treatment, 20 μ l of MTT solution (5 mg/ml) was added to each well for 4 h. The cells were then washed three times with PBS, and the resulting formazan was resuspended in 150 μ l dimethyl sulfoxide. Absorbance was measured at 570 nm with a Bio-Rad ELISA reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The experiment was repeated independently three times.

Flow cytometric assay for Annexin V apoptosis detection. Cell apoptosis was detected using an Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit (BD Biosciences, Franklin Lakes, NJ, USA). Briefly, HT-29 and SW620 cells were grown at a density of 5x10⁵ per well in 6-well plates. In accordance with the IC₅₀ values obtained from the MTT assay, the cells were treated with 0.01 or 0.05 mg/ml HVMEE for 24 h. Using the MTT assay results, the IC₅₀ values were 0.105±0.022 mg/ml for HT-29 and 0.146±0.013 mg/ml for SW620 cells. The authors identified that the minimum effective concentration of HVMEE

was 0.01 mg/ml for HT-29 and SW620 cells. Therefore, five times the minimum effective concentration of HVMEE was 0.05 mg/ml, which is a concentration with a significant effect, whilst bearing an apoptosis rate (for both HT-29 and SW620) of <50%.

Then, a total of 1x10⁶ cells were collected with centrifuge (700 x g) 3 min at room temperature, washed with ice-cold PBS and resuspended in 1X binding buffer [10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl₂] at a concentration of 1x10⁶ cells/ml. Annexin V-FITC (5 μ l of a 25 μ g/ml solution) and PI (5 μ l of a 250 μ g/ml solution) were added to 100 μ l of cell suspension. The cells were then gently vortexed and incubated at room temperature in the dark for 15 min. Then, 400 μ l of ice-cold binding buffer was added and mixed gently before the cell preparations were examined by flow cytometry (FACSCalibur; BD Biosciences).

Flow cytometric assay for nuclear DNA content distribution detection. To determine cell cycle distribution, cells were collected with centrifuge (700 x g) 3 min at room temperature, washed with ice-cold PBS and fixed for 2 h in 75% ethanol at -20°C. The cells were then treated with 1% RNase A for 5 min at 37°C and stained with 50 mg/ml PI for 30 min. Fluorescence intensity was examined by flow cytometry using a FACS Calibur (FACSCalibur; BD Biosciences).

Caspase-3 activity. Caspase-3 activity in HT-29 and SW620 cells was detected using the caspase-3 activity assay kit (Beyotime Institute of Biotechnology), as per the manufacturer's instructions. HT-29 and SW-620 cells were plated in culture dish (diameter, 10 cm) at a density of 1x10⁶ cells and allowed to grow for 24 h. The cells were then treated with HVMEE and Z-VAD-FMK (10 μ M) for 24 h or 48 h in complete medium with 37°C. Following drug treatment, absorbance values were measured at 405 nm. Results were adjusted to the total protein content, and activity was expressed as nmol of p-Nitroaniline per mg of total protein.

Western blot analysis. HT-29 and SW-620 cells were plated in culture dish (diameter, 10 cm) at a density of 10x10⁶ cells and allowed to grow for 24 h. Then, HT-29 cells and SW620 cells were treated with 0.01 and 0.05 mg/ml HVMEE for 24 and 48 h. The cells were then collected with a centrifuge (700 x g) 3 min at room temperature, and resuspended in lysis buffer (Beyotime Institute of Biotechnology) for 30 min in an ice bath. Following centrifugation at 14,000 x g at 4°C for 30 min, the supernatant was collected. Protein concentrations were determined using the Bradford method. Equal protein amounts (30 μ g) were separated by 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred electrophoretically to nitrocellulose membranes (Pall Corporation, New York, NY, USA) and blocked with TBS buffer containing 0.05% Tween-20 and 10% non-fat milk for 2 h at room temperature. The membranes were then incubated overnight at 4°C with various primary antibodies, followed by horseradish peroxidase-conjugated secondary antibodies at room temperature for 1.5 h. Following washing the membranes three times for 5 min in TBS buffer containing 0.05% Tween-20. Immunoreactive proteins on the membrane were detected using the Immobilon Western HRP substrate (EMD Millipore, Billerica, MA,




Figure 1. Total ion chromatogram of the sample solution. Cps, counts per second; 1, protopine; 2, allocryptopine; 3, berberine; 4, coptisine; 5, chelerythrine; 6, sanguinarine; 7, Tetrahydroberberine.




Figure 2. Effect of HVMEE treatment on colorectal cancer cell viability. Cell viability was measured by MTT assay in HT-29 and SW620 cells treated with 0, 0.01, 0.03, 0.1, 0.3, 1, and 3 mg/ml HVMEE for 24 h. Data are presented as % of live cells relative to control untreated cells. n=3 independent repeats. HVMEE, *Hylomecon vernalis* Maxim. ethanol extract.

USA). The bands were quantified using Multi Gauge version 3.2 software (Fujifilm Holdings Corporation, Tokyo, Japan). Experiments were repeated independently 3 times, and the relative expression of the target protein was normalized to the level of β -actin in the same sample.

Statistical analysis. SPSS software (version, 13.0; SPSS, Inc., Chicago, IL, USA) was used for the statistical analysis. Data were expressed as the mean \pm standard deviation. Statistical analyses were carried out using a one-way analysis of variance and Fisher's least significant difference (LSD) *t*-test to compare differences between groups. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Results of mass spectrometry. Ion flow results from HPLC analysis of the HVMEE are demonstrated in Fig. 1. The alkaloid content of the HVMEE was as high as 89.67%. The principal alkaloids observed were allocryptopine, protopine, berberine, sanguinarine, chelerythrine, tetrahydroberberine, and coptisine; their relative contents were 13.48, 55.33, 0.16, 14.86, 5.81, 0.002, and 0.02%, respectively (Fig. 1).

HVMEE decreases viability in HT-29 and SW620 cells. The effect of HVMEE on cell viability was assessed by MTT assay. As demonstrated in Fig. 2, HVMEE effectively decreased cell




Figure 3. Effect of HVMEE treatment on apoptosis. (A) HT-29 and (B) SW620 cells were treated with 0, 0.01 or 0.05 mg/ml HVMEE for 24 h, and apoptosis was detected using Annexin V-FITC/PI staining and flow cytometry analysis. (C) Quantification of apoptotic cells as % of total (sum of B2 and B4 quadrants). The experiment was repeated independently three times. * $P < 0.05$ and ** $P < 0.01$ vs. untreated control cells. HVMEE, *Hylomecon vernalis* Maxim. ethanol extract; B1, necrotic cells; B2, cells at end stage of apoptosis; B3, viable cells; B4, cells at the early stage of apoptosis; FITC, fluorescein isothiocyanate; PI, propidium iodide.

viability in HT-29 and SW620 cells in a concentration-dependent manner. The IC_{50} values were 0.105 ± 0.022 mg/ml for HT-29 and 0.146 ± 0.013 mg/ml for SW620 cells (Fig. 2).

HVMEE treatment triggers cell apoptosis. Apoptosis of HVMEE colorectal cancer cells was assessed by flow cytometry analysis. As demonstrated in Fig. 3, the percentages of apoptotic cells (the sum of B2 and B4 quadrants of the flow cytometry plots) in the untreated control HT-29 (Fig. 3A) and SW620 cells (Fig. 3B) were $3.7 \pm 0.3\%$ (Fig. 3A and C) and $4.9 \pm 0.2\%$ (Fig. 3B and C), respectively. When exposed to 0.01 mg/ml HVMEE for 24 h, the percentage of apoptotic cells increased to $15.3 \pm 1.4\%$ in the HT-29 cells ($P < 0.01$; Fig. 3A and C) and $9.9 \pm 1.8\%$ in the SW620 cells ($P < 0.05$; Fig. 3B and C). When exposed to 0.05 mg/ml of HVMEE for 24 h, the percentages of apoptotic cells increased to $27.7 \pm 1.3\%$ in the HT-29 cells ($P < 0.01$; Fig. 3A and C) and $19.7 \pm 0.7\%$ in the SW620 cells ($P < 0.01$; Fig. 3B and C). In addition, treatment

of HT-29 and SW620 cells with 0.01 and 0.05 mg/ml HVMEE resulted in a significant increase in caspase-3 activation in both cell lines compared with untreated control (Fig. 4). The HVMEE-induced caspase-3 activity was significantly blocked by pretreatment with a general caspase inhibitor, Z-VAD-FMK (Fig. 4).

HVMEE induces cell cycle arrest at the G_1 phase in HT-29 and SW620 cells. The cell cycle phase distribution in HT-29 (Fig. 5A) and SW620 (Fig. 5B) cells was examined following treatment with 0.01 and 0.05 mg/ml HVMEE for 24 h. Flow cytometric analysis of nuclear DNA distribution demonstrated a concentration-dependent increase of G_1 proportions in HVMEE-treated cells, compared with untreated control cells (Fig. 5).

HVMEE affects apoptosis-related protein expression. Following 24 and 48 h of 0.01 and 0.05 mg/ml HVMEE




Figure 4. Effect of HVMEE treatment on caspase-3 activity. HT-29 and SW620 cells were treated with 0.01 or 0.05 mg/ml HVMEE for 24 or 48 h, following which caspase-3 activity was measured. Treatment with the general caspase inhibitor Z-VAD-FMK (10 μ M) for 24 h or 48 h with 0.05 mg/ml HVMEE. **P<0.01 vs. untreated control cells. ##P<0.01 vs. treatment with 0.05 mg/ml HVMEE. The experiment was repeated independently three times. HVMEE, *Hylomecon vernalis* Maxim. ethanol extract; pNA, p-nitroaniline; Z-VAD-FMK, N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone.

treatment in HT-29 and SW620 cells, expression levels of several apoptosis-related proteins were examined by western blotting (Fig. 6A and B, respectively). Expression levels of pro-apoptotic proteins cleaved caspase-3, cleaved caspase-9, and Bax increased in HVMEE-treated cells compared with

untreated cells (Fig. 6). Expression levels of cleaved caspase-8 presented no significant change (Fig. 6). By contrast, expression levels of Bcl-2, an apoptosis inhibitor and a central regulator of caspase activation, significantly decreased in the HVMEE-treated cells compared with untreated cells (Fig. 6).

HVMEE affects cell cycle-related protein expression. To test the mechanisms of HVMEE-induced cell cycle arrest, expression of cell cycle-related proteins was further assessed by western blotting. Following treatment of HT-29 and SW620 cells with 0.01 and 0.05 mg/ml HVMEE for 24 and 48 h, the expression levels of cyclin D1, cyclin dependent kinase (CDK) 4, and CDK6 decreased significantly in HVMEE-treated cells compared with the untreated cells (Fig. 7). By contrast, protein expression levels of cyclin dependent kinase inhibitor 1A (known as p21) were significantly upregulated in the HVMEE-treated cells compared with the untreated cells (Fig. 7). Since induction of p21 leads to CDK inhibition and cell cycle arrest at the G₁/S checkpoint (9-11), these data indicate that the HVMEE-induced G₁ phase arrest may be due to inhibition of CDK4/6-cyclin D1 complexes by p21 upregulation.

Discussion

Apoptosis is an important process to maintain tissue homeostasis by eliminating potentially deleterious cells. Deregulated apoptotic cell death causes diseases, such as cancer. In cancer cells, the incidence of apoptosis and the rate of cell proliferation are uncontrolled (12,13). Therefore, inducing




Figure 5. Effect of HVMEE treatment on cell cycle phase distribution. (A) HT29 and (B) SW620 cells were treated with 0, 0.01 or 0.05 mg/ml HVMEE for 24 h, and cell cycle phase distribution was analyzed by flow cytometry. Numbers in the plots denote the % of total cells in the G1 phase. The experiment was repeated independently three times. HVMEE, *Hylomecon vernalis* Maxim. ethanol extract.




Figure 6. Effect of HVMEE treatment on apoptosis-related protein expression. (A) HT29 and (B) SW620 cells were treated with 0.01 or 0.05 mg/ml HVMEE for 24 and 48 h, then expression levels of apoptosis-related proteins cleaved caspase-3, -8, -9, Bax and Bcl-2 were examined by western blotting. β -actin was used as an internal reference for normalization of signals. * $P < 0.05$ and ** $P < 0.01$ vs. untreated control cells. HVMEE, *Hylomecon vernalis* Maxim. ethanol extract; Bcl-2, BCL2 apoptosis regulator; Bax, BCL2 associated X apoptosis regulator. The experiment was repeated independently three times.




Figure 7. Effect of HVMEE treatment on cell cycle-related protein expression. (A) HT29 and (B) SW620 cells were treated with 0.01 or 0.05 mg/ml HVMEE for 24 and 48 h, then expression levels of cell cycle-related proteins CDK4, CDK6, cyclin D1 and p21 were examined by western blotting. * $P < 0.05$ and ** $P < 0.01$ vs. untreated control cells. HVMEE, *Hylomecon vernalis* Maxim. ethanol extract; CDK, cyclin dependent kinase; p21, cyclin dependent kinase inhibitor 1A. The experiment was repeated independently three times.

apoptosis is a potential method of treating cancer. Several chemotherapy drugs, including 5-FU, irinotecan, and oxaliplatin, display anticancer effects partly by inducing apoptosis in cancer cells (14-16). In addition, many alkaloids, such as 6-Acetyldihydrochelerythrine, piperine, and monoterpene bisindole alkaloids, exert antitumor functions by affecting apoptosis (14-16). In the present study, flow cytometry was used to analyze the effects of HVMEE on apoptosis of colon cancer cell lines HT-29 and SW620. The HT-29 cell line originated from the primary tumor tissue of a colorectal cancer patient, while the SW620 cell line originated from a lymph node metastatic site of a colorectal cancer patient with a Dukes' C classification (17,18). Therefore, these two cell lines were selected to test the effects of HVMEE in order to represent the two different states of colorectal cancer, at the primary and the metastatic stage, respectively. The findings from the MTT and flow cytometry assays demonstrated that HVMEE exhibited a more potent effect on HT-29 cells than SW620 cells, indicating that HVMEE may be more efficient in treating primary rather than metastatic colorectal cancer.

Caspases, a family of cysteine proteases, are central regulators of apoptosis. Caspase-8 is involved in the death receptor apoptotic pathway and caspase-9 is involved in the mitochondrial apoptotic pathway. Following activation, they cleave and activate downstream effectors, such as caspase-3, which subsequently cleave cytoskeletal and nuclear proteins (19). Western blot analysis demonstrated that HVMEE treatment increased the expression levels of cleaved caspase-3 and -9, but had no significant effect on expression of cleaved caspase-8. HVMEE-induced caspase-3 cleavage was prevented by pretreatment of HT-29 and SW620 cells with a pan-caspase inhibitor, Z-VAD-FMK. These data suggest that HVMEE induced apoptosis in CRC cells in a caspase-dependent manner.

The Bcl-2 protein family, which is important in the mitochondrial apoptotic pathway and whose abnormal expression is related to the development of CRC (20), is divided into two functional subfamilies: Anti-apoptotic proteins [(Bcl-2 and BCL2-like 1 (Bcl-xL)] and pro-apoptotic proteins [(Bax and BH3 interacting domain death agonist (Bid)] (21,22). HVMEE greatly reduced Bcl-2 expression and increased Bax expression in a time and concentration-dependent manner, suggesting that HVMEE triggered apoptosis in CRC cells by regulating the Bax/Bcl-2 protein ratio.

The transition from one cell cycle phase to another occurs in an orderly fashion and is regulated by two types of important components: Cyclins and CDKs. Different cyclins reach their maximum activity levels during different phases of the cell cycle (23,24). In the present study, HVMEE treatment was demonstrated to trigger G₁ phase arrest. In order to explore the mechanism, expression of proteins associated with G₁ phase transition was further investigated. Cyclin D1 is overexpressed in many human cancers, including CRC, and it binds to CDK4 and CDK6 to form a CDK4/6-cyclin D1 complex, which is essential for cells to enter the G₁ phase (9). Western blot analysis demonstrated that HVMEE treatment decreased expression levels of cyclin D1, CDK4, and CDK6 compared to untreated cells. p21, which prevents the replication of damaged DNA, is important in CDK inhibition and G₁ phase arrest (10,11). HVMEE treatment increased p21 expression compared with untreated cells. Therefore, HVMEE may induce G₁ arrest in

CRC cells partly through upregulation of p21 expression. Of note, p53 expression levels in HVMEE-treated HT-29 and SW620 cells exhibited no significant change compared with the untreated cells (data not shown). HT-29 cells have a mutant p53 gene which suggests that p53 may not be as significant in cell cycle and apoptosis regulation in HT-29 cells (25). Taken together, these findings imply that HVMEE induced cell cycle apoptosis and arrest in a p53-independent manner.

In conclusion, HVMEE was obtained from *Hylomecon vernalis* and demonstrated to exhibit a potent growth inhibitory effect in HT-29 and SW620 colorectal carcinoma cells. The possible mechanism of HVMEE antitumor effect may be related to inducing apoptosis and G₁ phase arrest. These data suggest that HVMEE may have potential in the clinical prevention and treatment of colon cancer.

Acknowledgements

The present investigation was supported by The Project of Science and Technology Research and Development of Shaanxi Province (grant nos. 2012SF2-07 and 2013KJXX-71).

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136: E359-E386, 2015.
2. Winawer SJ: The multidisciplinary management of gastrointestinal cancer. Colorectal cancer screening. *Best Pract Res Clin Gastroenterol* 21: 1031-1048, 2007.
3. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, *et al*: A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med* 348: 891-899, 2003.
4. Liang CH, Liu LF, Shiu LY, Huang YS, Chang LC and Kuo KW: Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells. *Biochem Biophys Res Commun* 322: 751-758, 2004.
5. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. *Anticancer Res* 24: 2783-2840, 2004.
6. Yang H, Yin P, Shi Z, Ma Y, Zhao C, Zheng J and Chen T: Sinomenine, a COX-2 inhibitor, induces cell cycle arrest and inhibits growth of human colon carcinoma cells in vitro and in vivo. *Oncol Lett* 11: 411-418, 2016.
7. Kong LM, Feng T, Wang YY, Li XY, Ye ZN, An T, Qing C, Luo XD and Li Y: Bisleuconothine A, a bisindole alkaloid, inhibits colorectal cancer cell in vitro and in vivo targeting Wnt signaling. *Oncotarget* 7: 10203-10214, 2016.
8. Li W, Wen C, Bai H, Wang X, Zhang X, Huang L, Yang X, Iwamoto A and Liu H: JNK signaling pathway is involved in piperlongumine-mediated apoptosis in human colorectal cancer HCT116 cells. *Oncol Lett* 10: 709-715, 2015.
9. Sherr CJ: G1 phase progression: Cycling on cue. *Cell* 79: 551-555, 1994.
10. Ko LJ and Prives C: p53: Puzzle and paradigm. *Genes Dev* 10: 1054-1072, 1996.
11. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E and Kastan MB: DNA damage induces phosphorylation of the amino terminus of p53. *Genes Dev* 11: 3471-3481, 1997.
12. Rudolf E, Kralova V, Rudolf K and John S: The role of p38 in irinotecan-induced DNA damage and apoptosis of colon cancer cells. *Mutat Res* 741-742: 27-34, 2013.
13. Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C, Lesser M, Mariadason JM and Augenlicht LH: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. *Br J Cancer* 91: 1931-1946, 2004.
14. Mansoor TA, Borralho PM, Luo X, Mulhovo S, Rodrigues CM and Ferreira MJ: 6-Acetyldihydrochelerythrine is a potent inducer of apoptosis in HCT116 and SW620 colon cancer cells. *J Nat Prod* 77: 1825-1830, 2014.

15. Yaffe PB, Power Coombs MR, Doucette CD, Walsh M and Hoskin DW: Piperine, an alkaloid from black pepper, inhibits growth of human colon cancer cells via G1 arrest and apoptosis triggered by endoplasmic reticulum stress. *Mol Carcinog* 54: 1070-1085, 2015.
16. Mansoor TA, Borralho PM, Dewanjee S, Mulhovo S, Rodrigues CM and Ferreira MJ: Monoterpene bisindole alkaloids, from the African medicinal plant *Tabernaemontana elegans*, induce apoptosis in HCT116 human colon carcinoma cells. *J Ethnopharmacol* 149: 463-470, 2013.
17. Abdolahad M, Shashaani H, Janmaleki M and Mohajerzadeh S: Silicon nanograss based impedence biosensor for label free detection of rare metastatic cells among primary cancerous colon cells, suitable for more accurate cancer staging. *Biosens Bioelectron* 59: 151-159, 2014.
18. Jordan A, Scholz R, Schüler J, Wust P and Felix R: Arrhenius analysis of the thermal response of human colonic adenocarcinoma cells in vitro using the multi-target, single-hit and the linear-quadratic model. *Int J Hyperthermia* 13: 83-88, 1997.
19. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. *J Biol Chem* 274: 22932-22940, 1999.
20. Li XF, Liu XF, Yang YY, Liu AY, Zhang MY, Bai XF, Gao H and Guo XG: Correlation study of Bcl-2, B7-H1, EGFR, VEGF and colorectal cancer. *Am J Cancer Res* 5: 2277-2284, 2015.
21. Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N, Elssner C, Welte S, Bermejo JL, Jäger D and Schulze-Bergkamen H: Beyond cell death-antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. *PLoS One* 8: e76446, 2013.
22. Hector S and Prehn JH: Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review. *Biochim Biophys Acta* 1795: 117-129, 2009.
23. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: A novel investigational antimicrotubule agent. *J Natl Cancer Inst* 82: 1247-1259, 1990.
24. Hamilton G, Klameth L, Rath B and Thalhammer T: Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. *Molecules* 19: 2077-2088, 2014.
25. Harper JW: Cyclin dependent kinase inhibitors. *Cancer Surv* 29: 91-107, 1997.